MedTrace Logo

Pulp Capping in Primary Molars Using TheraCal (LC)

NCT05167123 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-02-03

No results posted yet for this study

Summary

A randomized clinical trial that aims to evaluate clinical and radiographic success rates of indirect pulp capping and direct pulp capping in primary molars with reversible pulpitis using a light-cured tri-calcium silicate base material (TheraCal (LC)).

Conditions

  • Deep Caries
  • Indirect Pulp Capping
  • Direct Pulp Capping
  • Reversible Pulpitis
  • Decayed Teeth
  • Vital Pulp Therapy

Interventions

DRUG

Light cured tri-calcium silicate base material

TheraCal (LC) (BISCO Inc., Schamburg, IL, USA) was introduced in (2011), are available commercially as flowable cement applicable via syringe

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Yomna Hussein Moselhy, M.Sc. · Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
7 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2021-11-30
Completion
2021-12-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05167123 on ClinicalTrials.gov